BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1190
Portfolio Pulse from Benzinga Newsdesk
BMO Capital has maintained an 'Outperform' rating on Regeneron Pharmaceuticals but has lowered the price target from $1300 to $1190.

November 01, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BMO Capital has maintained an 'Outperform' rating on Regeneron Pharmaceuticals but has lowered the price target from $1300 to $1190.
The 'Outperform' rating suggests continued confidence in Regeneron's performance, but the lowered price target indicates a more conservative outlook on its valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100